The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.
In this video, David takes a closer look at biotech's two worst stocks in 2012. Beaten down companies are often underperforming for a reason, but sometimes the negativity provides a nice entry point. Shares for both of these companies are off more than 50% after trial difficulties -- watch and discover which is a stay away and which may be a possible buy.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.David Williamson owns shares of Pfizer. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.